10.15.13
Johnson & Johnson
3Q Revenues: $17.6 billion (+3%)
3Q Earnings: $3.0 billion (flat)
YTD Revenues: $53.0 billion (+1%)
YTD Earnings: $10.3 billion (+25%)
Comments: Pharmaceutical sales were $7.0 billion in the quarter, up 10%. Domestic sales were up 8%. International sales increased 12%. Growth was driven by Invega Sustenna/Xeplion ($324 million, +53%), Remicade ($1.7 billion, +6%), Simponi ($266 million, +44%), Stelara ($370 million, +29%), Velcade ($404 million, +24%), and Prezista ($410 million, +13%), as well as strong sales of new products Zytiga ($464 million, +75%), and Xarelto ($246 million, +68%). R&D expenses were up 6% to $2.0 billion in the quarter. Consumer sales were $3.6 billion, up 2% in the quarter, and Medical Devices & Diagnostics sales down 2% to were $6.9 billion.
3Q Revenues: $17.6 billion (+3%)
3Q Earnings: $3.0 billion (flat)
YTD Revenues: $53.0 billion (+1%)
YTD Earnings: $10.3 billion (+25%)
Comments: Pharmaceutical sales were $7.0 billion in the quarter, up 10%. Domestic sales were up 8%. International sales increased 12%. Growth was driven by Invega Sustenna/Xeplion ($324 million, +53%), Remicade ($1.7 billion, +6%), Simponi ($266 million, +44%), Stelara ($370 million, +29%), Velcade ($404 million, +24%), and Prezista ($410 million, +13%), as well as strong sales of new products Zytiga ($464 million, +75%), and Xarelto ($246 million, +68%). R&D expenses were up 6% to $2.0 billion in the quarter. Consumer sales were $3.6 billion, up 2% in the quarter, and Medical Devices & Diagnostics sales down 2% to were $6.9 billion.
